Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humanigen, Inc.

https://www.humanigen.com/

Latest From Humanigen, Inc.

Humanigen Raises Chances of Lenzilumab EUA With Severe COVID-19 Data

Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.

Coronavirus COVID-19 Clinical Trials

Finance Watch: Investors Launch New SPACs After Initial Deals

EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.

Finance Watch Innovation

Humanigen Data Show Success In High-Risk COVID-19 Population

Phase III results show benefit in cytokine-release syndrome, while other drugs for treating patients hospitalized with COVID-19 have produced mixed results.

Commercial Research and Development Strategies

Coronavirus Update: How Vaccines Stack Up Against Variants So Far

Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.

Research & Development Research and Development Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • KaloBios Pharmaceuticals, Inc.
    • Humanigen Australia Pty Ltd
UsernamePublicRestriction

Register